DotLab's Products & Differentiators
DotEndo is harnessing DotLab's expertise with novel, cutting-edge biomarkers and the power of machine learning to deliver the first non-invasive tool to diagnose endometriosis, resulting in a paradigm shift in the identification and management of the disease.
Research containing DotLab
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned DotLab in 1 CB Insights research brief, most recently on Nov 11, 2022.
Latest DotLab News
Oct 26, 2022
DotLab is a company on a mission to solve some of the world’s most significant diagnostic challenges via the latest advancements in multiomics and computational biology. The company delivers clinical innovations to areas of significant unmet need. The company is harnessing its expertise with novel, cutting-edge biomarkers and the power of machine learning to deliver non-invasive tests, starting with endometriosis. This past…
DotLab Frequently Asked Questions (FAQ)
When was DotLab founded?
DotLab was founded in 2016.
Where is DotLab's headquarters?
DotLab's headquarters is located at 3749 Buchanan Street, San Francisco.
What is DotLab's latest funding round?
DotLab's latest funding round is Series A.
How much did DotLab raise?
DotLab raised a total of $10M.
Who are the investors of DotLab?
Investors of DotLab include Tiger Global Management, Cooper Surgical, Luxor Capital Group, Berkeley SkyDeck and Yale University.
Who are DotLab's competitors?
Competitors of DotLab include Scailyte and 2 more.
What products does DotLab offer?
DotLab's products include DotEndo.
Compare DotLab to Competitors
AbbVie (NYSE: ABBV) researches and develops pharmaceutical products. The company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. It also offers treatments for diseases including multiple sclerosis, Parkinson's, and Alzheimer's disease. The company was founded in 2013 and is based in North Chicago, Illinois.
Owkin specializes in developing artificial intelligence (AI) technologies for clinical research and developing drugs and treatments for patients. It empowers researchers in hospitals, universities, and the biopharmaceutical industry to understand drug efficacy varies, improves the drug development process, and help identify key drugs and treatments for individual patients to improve patient outcomes. The company was founded in 2016 and is based in New York, New York.
Immunai operates as a biotechnology company. It maps the immune system with single-cell biology and artificial intelligence (AI) to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes. The company was founded in 2018 and is based in New York, New York.
Ziwig specializes in the development of a healthcare platform designed to manage the management of endometriosis. The company's platform integrates patients, health specialists, and artificial intelligence and machine learning specialists that help in the possible detection of chronic women's diseases. The company was founded in 2020 and is based in Lyon, France.
NextGen Jane offers women insights into their reproductive health through a genomics-driven approach to tracking biological changes predictive of disease. Its smart tampon allows women to proactively keep track of their health by studying blood samples in the privacy of their homes. The company was founded in 2014 and is based in Oakland, California.
Temple Therapeutics is a pharmaceutical clinical development company with a global footprint, focused on diseases where abnormal tissue growth and dysfunction are common hallmarks and lead to fibrosis, pain, infertility, and cancers. The company was founded in 2020 and is based in Geleen, Netherlands.